Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Hoyoung Maeng(National Cancer Institute), Jay A. Berzofsky(National Cancer Institute), Svetlana Pack(National Cancer Institute), Lee England(National Cancer Institute), Markku Miettinen(National Cancer Institute), Frederic G. Barr, Jon R. Inglefield(Frederick National Laboratory for Cancer Research), Lauren V. Wood(National Cancer Institute), Seth M. Steinberg(National Cancer Institute), Louis M. Weiner(Georgetown University), Brenda Roberson(National Cancer Institute), David F. Stroncek(Yale University), Wei‐Zen Wei(Wayne State University), Kim Dunham(Frederick National Laboratory for Cancer Research), Brittni N. Moore(National Institutes of Health), Douglas R. Rosing(National Heart Lung and Blood Institute), Masaki Terabe(National Cancer Institute), Hadi Bagheri(National Institutes of Health Clinical Center), Sandhya R. Panch(National Institutes of Health Clinical Center), John C. Morris(University of Cincinnati), Vandana Sachdev(National Heart Lung and Blood Institute)
Cited by 26
Related Papers
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Monoclonal Antibodies in Cancer Therapy
|Antibodies|2020|799
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371